Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

359
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
359
Seizures: Classification01:13

Seizures: Classification

675
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
675
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

519
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
519

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

6-Month Recovery after Mild Traumatic Brain Injury in Older Adults: A TRACK-GERI Study.

medRxiv : the preprint server for health sciences·2026
Same author

Clinical and Economic Burden of Poor Bone Health in Adult Spinal Deformity Surgery: A Multicenter Cohort Study.

Spine·2026
Same author

Comparison of Bilateral and Unilateral Chronic Subdural Hematomas: A Retrospective Multi-institutional Cohort Study.

Neurosurgery practice·2026
Same author

Full-Body Radiographic Imaging-Based Thigh Muscle Measurement for Sarcopenia: Association with Functional Assessments and Sagittal Alignment in Adult Spinal Deformity Patients.

Spine·2026
Same author

Development of a Novel Blood-Based Assay for Brain-Derived Tau and Its Validation in Traumatic Brain Injury.

medRxiv : the preprint server for health sciences·2026
Same author

Post-Operative Coronal Malalignment is Associated with Delayed Deterioration Following Minimally Invasive Surgery for Adult Spinal Deformity.

Spine·2026

Related Experiment Video

Updated: Oct 14, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

505

Early Seizure Prophylaxis in Mild and Moderate Traumatic Brain Injury: A Systematic Review and Meta-Analysis.

Matthew Pease1, Adi Mittal2, Sara Merkaj3

  • 1Department of Neurosurgery, Indiana University School of Medicine, Indianapolis.

JAMA Neurology
|April 8, 2024
PubMed
Summary

Seizure prophylaxis for mild to moderate traumatic brain injury (TBI) showed a small, significant reduction in early posttraumatic seizures (PTS). The low absolute risk reduction necessitates careful consideration of medication risks versus benefits.

More Related Videos

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury
07:07

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury

Published on: February 10, 2020

10.5K
Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
09:16

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury

Published on: June 21, 2019

25.6K

Related Experiment Videos

Last Updated: Oct 14, 2025

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment
08:36

Author Spotlight: Evaluating the Adjuvant Efficacy and Safety of Angong Niuhuang Pill in Viral Encephalitis Treatment

Published on: April 19, 2024

505
Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury
07:07

Inducing Post-Traumatic Epilepsy in a Mouse Model of Repetitive Diffuse Traumatic Brain Injury

Published on: February 10, 2020

10.5K
Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury
09:16

Use of a Wireless Video-EEG System to Monitor Epileptiform Discharges Following Lateral Fluid-Percussion Induced Traumatic Brain Injury

Published on: June 21, 2019

25.6K

Area of Science:

  • Neurology
  • Trauma Care
  • Clinical Research

Background:

  • Guidelines recommend seizure prophylaxis for severe traumatic brain injury (TBI) to prevent early posttraumatic seizures (PTS).
  • The use of antiseizure medications for seizure prophylaxis in mild or moderate TBI remains a subject of debate.

Purpose of the Study:

  • To evaluate the association between seizure prophylaxis and the reduction of early PTS risk in patients with mild or moderate TBI.
  • To analyze the efficacy of seizure prophylaxis specifically in mild TBI cases.

Main Methods:

  • A systematic literature search was conducted across PubMed, Google Scholar, and Web of Science from 1991 to 2023.
  • Included observational studies of adult patients with mild (Glasgow Coma Scale [GCS] 13-15) or moderate (GCS 9-12) TBI, comparing early PTS rates with and without seizure prophylaxis.
  • Meta-analysis was performed using a random-effects model, adhering to PRISMA guidelines.

Main Results:

  • Eight studies involving 5637 patients were analyzed for mild to moderate TBI.
  • Seizure prophylaxis demonstrated a statistically significant absolute risk reduction of 0.6% for early PTS in mild to moderate TBI (P=.02).
  • A similar absolute risk reduction of 0.6% was observed for mild TBI alone (P=.04), with a number needed to treat of 167.

Conclusions:

  • Seizure prophylaxis is associated with a small but statistically significant reduction in early PTS for mild and moderate TBI.
  • The clinical relevance of this small risk reduction must be balanced against the potential acute risks of antiseizure medications and the possibility of prolonged use.